CLINICAL_TRIALS
trial_result
· 2014-05-23
Clinical Trial Update: A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy [Phase 2]
Summary
A Phase 2 safety and effectiveness study of a single dose of JNJ-17216498 in patients with narcolepsy has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Alza Corporation, DE, USA | Conditions: Narcolepsy | Phase 2 | Status: COMPLETED